The clinical use of angiotensin-converting enzyme inhibitors

Pratt, 1999, Angiotensin II and the control of cardiovascular structure, J Am Soc Nephrol, 10, S120 Skott, 1993, Cellular and intrarenal control of renin secretion, Clin Sci (Lond), 84, 1, 10.1042/cs0840001 Barley, 1996, Angiotensin converting enzyme gene I/D polymorphism blood pressure and the renin-angiotensin system in Caucasian and Afro-Caribbean peoples, J Hum Hypertens, 10, 31 Yoshida, 1995, Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy, J Clin Invest, 96, 2162, 10.1172/JCI118270 Adams, 1998, Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease, Coron Artery Dis, 9, 675, 10.1097/00019501-199809100-00007 Scharschmidt, 1983, Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin, J Clin Invest, 7, 1756, 10.1172/JCI110931 Hornig, 1998, Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure, Circulation, 98, 2842, 10.1161/01.CIR.98.25.2842 Unger, 2000, Neurohormonal modulation in cardiovascular disease, Am Heart J, 139, 52, 10.1067/mhj.2000.102901 Sadoshima, 2000, Cytokine actions of angiotensin II, Circ Res, 86, 1187, 10.1161/01.RES.86.12.1187 Nakajima, 1995, The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor, Proc Natl Acad Sci U S A, 92, 10663, 10.1073/pnas.92.23.10663 Keidar, 2001, Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL, Arterioscler Thromb Vasc Biol, 21, 1464, 10.1161/hq0901.095547 Massie, 2001, Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure, Arch Intern Med, 161, 165, 10.1001/archinte.161.2.165 Hennig, 2002, Clinical studies on the therapy of heart failure using ACE-inhibitors and AT1-receptor blockers—Does combination treatment make sense?, Clin Nephrol, 58, S7 Nussberger, 1985, Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans, J Hypertens, S269 Massie, 2001, Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: Results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival, Arch Intern Med, 161, 165, 10.1001/archinte.161.2.165 Lewington, 2002, Age-specific prevalence usual blood pressure to vascular mortality, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 McMurray, 2003, CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3 Neal, 2000, Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs, Lancet, 356, 1955, 10.1016/S0140-6736(00)03307-9 Chobanian, 2003, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Yusuf, 2001, Ramipril and the development of diabetes, JAMA, 286, 1882, 10.1001/jama.286.15.1882 Pepine, 2003, A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial, JAMA, 290, 2805, 10.1001/jama.290.21.2805 2003, Diuretic versus [alpha]-blocker as first-step antihypertensive therapy, Hypertension, 42, 239 1987, Effects on enalapril on mortality in sever congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 1991, Effect of enalapril n survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 Cohn, 1991, A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure, N Engl J Med, 325, 303, 10.1056/NEJM199108013250502 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular fractions, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003 Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trail, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001 1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure, Lancet, 342, 821 1994, The TRAndolapril Cardiac Evaluation (TRACE) study, Am J Cardiol, 73, 44C, 10.1016/0002-9149(94)90623-8 Banerjee, 2002, Diastolic heart failure, J Am Coll Cardiol, 39, 138, 10.1016/S0735-1097(01)01704-1 Ryan, 1999, 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction), Circulation, 100, 1016, 10.1161/01.CIR.100.9.1016 Latini, 1995, ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials, Circulation, 92, 3132, 10.1161/01.CIR.92.10.3132 Sigurdsson, 1994, Left ventricular remodeling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction, Eur Heart J, 15, 14, 10.1093/eurheartj/15.suppl_B.14 Aronow, 2001, Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction, Am J Cardiol, 88, 1298, 10.1016/S0002-9149(01)02092-6 Vaughan, 1997, Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition, Clin Cardiol, 20, II.34 Hamsten, 1987, Plasminogen activator inhibitors in plasma, Lancet, 11, 319 Brown, 2000, Prothrombotic effects of angiotensin, Adv Intern Med, 45, 419 Tsikouris, 2004, Questioning a class effect, J Clin Pharmacol, 44, 150, 10.1177/0091270003262103 Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292 Pedersen, 1997, Trandolapril reduces the incidence of atrial fibrillation following acute myocardial infarction, Circulation, 96, 75-I Vermes, 2003, Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction, Circulation, 107, 2926, 10.1161/01.CIR.0000072793.81076.D4 Yusuf, 2000, Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Eng J Med, 342, 145, 10.1056/NEJM200001203420301 Anderson, 2000, Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow mediated vasodilatation in patients with coronary artery disease (BANFF), J Am Coll Cardiol, 35, 60, 10.1016/S0735-1097(99)00537-9 Mancini, 1996, Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study, Circulation, 94, 258, 10.1161/01.CIR.94.3.258 Fox, 2003, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease, Lancet, 362, 782, 10.1016/S0140-6736(03)14286-9 Kjoller-Hansen, 2000, The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES), J Am Coll Cardiol, 35, 881, 10.1016/S0735-1097(99)00634-8 Bosch, 2002, Use of ramipril in preventing stroke, BMJ, 324, 699, 10.1136/bmj.324.7339.699 2001, Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack, Lancet, 358, 1033, 10.1016/S0140-6736(01)06178-5 Lewis, 1993, The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuria, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Laverman, 2002, Dual renin-angiotensin system blockade at optimal doses for proteinuria, Kidney Int, 62, 1020, 10.1046/j.1523-1755.2002.00536.x Rossing, 2003, Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy, Diabetes Care, 26, 2268, 10.2337/diacare.26.8.2268 Maschio, 1996, Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 Israili, 1992, Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology, Ann Intern Med, 117, 234, 10.7326/0003-4819-117-3-234 Guazzi, 2003, Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure, Arch Intern Med, 163, 1574, 10.1001/archinte.163.13.1574 Spinale, 1997, Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes, Circulation, 96, 2397, 10.1161/01.CIR.96.7.2397 Mankad, 2001, Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling, Circulation, 103, 2845, 10.1161/01.CIR.103.23.2845 Di Pasquale, 1999, Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study, Heart, 81, 606, 10.1136/hrt.81.6.606 Tikkanen, 1995, Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension, J Hypertens, 13, 1343, 10.1097/00004872-199511000-00017 Jong, 2002, Angiotensin receptor blockers in heart failure, J Am Coll Cardiol, 39, 463, 10.1016/S0735-1097(01)01775-2 Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489 Kober, 1995, A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 333, 1670, 10.1056/NEJM199512213332503